TY - JOUR
T1 - Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease
AU - Texas Alzheimer's Research Care Consortium
AU - Hall, James R.
AU - Wiechmann, April R.
AU - Cunningham, Rebecca L.
AU - Johnson, Leigh A.
AU - Edwards, Melissa
AU - Barber, Robert C.
AU - Singh, Meharvan
AU - Winter, Scott
AU - O'Bryant, Sid E.
N1 - Funding Information:
This research was conducted under a protocol approved by the institutional review committees of Baylor College of Medicine, Texas Tech University Health Sciences Center, University of North Texas Health Science Center, University of Texas Southwestern Medical Center and University of Texas Health Science Center–San Antonio. The research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under awards R01 AG039389 and P30 AG12300. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This study was made possible by the Texas Alzheimer’s Research and Care Consortium (TARCC), which is funded by the State of Texas through the Texas Council on Alzheimer’s Disease and Related Disorders. The funders had no role in study design, data collection, analysis, decision to publish or preparation of the manuscript. Texas Alzheimer’s Research and Care Consortium investigators: Baylor College of Medicine: Rachelle Doody, MD, PhD; Susan Roundtree, MD; Valory Pavlik, PhD; Wen Chan, PhD; Paul Massman, PhD; Eveleen Darby; and Tracey Evans. Texas Tech University Health Sciences Center: Benjamin Williams, MD; Gregory Schrimsher, PhD; Andrew Dentino, MD; and Ronnie Orozco. University of North Texas Health Science Center: Thomas Fairchild, PhD; Janice Knebl, DO; Douglas Mains; and Lisa Alvarez. University of Texas Southwestern Medical Center: Perrie Adams, PhD; Roger Rosenberg, MD; Myron Weiner, MD; Mary Quiceno, MD; Joan Reisch, PhD; Ryan Huebinger, PhD; Guanghua Xiao, PhD; Doris Svetlik; Amy Werry; and Janet Smith. University of Texas Health Science Center–San Antonio: Donald Royall, MD; Raymond Palmer, PhD; and Marsha Polk.
Publisher Copyright:
© 2015 Hall et al.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Abstract Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD. Methods: The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43). Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors. Conclusions: The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.
AB - Abstract Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD. Methods: The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43). Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors. Conclusions: The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.
UR - http://www.scopus.com/inward/record.url?scp=84928610205&partnerID=8YFLogxK
U2 - 10.1186/s13195-015-0107-4
DO - 10.1186/s13195-015-0107-4
M3 - Article
AN - SCOPUS:84928610205
SN - 1758-9193
VL - 7
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 107
ER -